title: Pharmacogenomics panel test for prevention toxicity in patient who receive Fluoropirimidine/Oxaliplatin-based therapy.
abstract: OBJECTIVE
  Both Fluoropirimidine and Oxaliplatin (FluOx) are the most common anticancer drugs used to treat lung, colorectal, ovarian, breast, head/neck, and genitourinary cancers. However, the efficacy of FluOx-based therapy is often compromised because of the severe risk of toxicity. Stratification of patients for multidrug response is a promising strategy for cancer treatment and personalized therapy.
  
  
  METHODS
  Here, we review the late findings on the most appropriate gene variants related to the toxicity in patients receiving FluOx chemotherapy. Several criteria were used to select a genotyping panel tests, including dihydropyrimidine dehydrogenase (DPYD), thymidylate synthase (TYMS), Glutathione S-transferase (GSTP1), and ATP-binding cassette, subfamily C member 2 (ABCC2).
  
  
  RESULTS
  Results of allelic status from 7 validated polymorphism assays, allow the stratification of the patients who are most likely to respond to FluOx treatments. Also, we will take in consideration the usefulness and costs of the methods used to detect these polymorphisms.
  
  
  CONCLUSIONS
  With these pharmacogenomics markers, the oncologists will have new means based on the genetic profile of the individual, to make treatment decisions for their patients in order to maximize benefits and minimize toxicity.
authors.affiliation: National Cancer Institute, Fondazione G. Pascale IRCCS, Naples, Italy. rdifrancia@iapharmagen.org
authors.forename: R
authors.initials: R
authors.lastname: Di Francia
authors.forename: R S
authors.initials: RS
authors.lastname: Siesto
authors.forename: D
authors.initials: D
authors.lastname: Valente
authors.forename: D
authors.initials: D
authors.lastname: Spart
authors.forename: M
authors.initials: M
authors.lastname: Berretta
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000235:genetics; D005472:Fluorouracil / Q000009:adverse effects*; D005838:Genotype; D006801:Humans; D000089762:Multidrug Resistance-Associated Protein 2; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D013940:Thymidylate Synthase / Q000235:genetics
chemical_list: C000715087:ABCC2 protein, human; D000970:Antineoplastic Agents; D000089762:Multidrug Resistance-Associated Protein 2; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D042943:Dihydrouracil Dehydrogenase (NADP); D013940:Thymidylate Synthase; D005472:Fluorouracil